BACKGROUND: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality among individuals with dyssynchronous systolic heart failure (HF). However, patient outcomes vary, with some at higher risk than others for HF progression and death. OBJECTIVE: To develop a risk prediction score incorporating variables associated with mortality, left ventricular assist device (LVAD) implant, or heart transplant in recipients of a primary prevention cardiac resynchronization therapy-defibrillator (CRT-D). METHODS: We followed 305 CRT-D patients from the Prospective Observational Study of Implantable Cardioverter-Defibrillators for the composite outcome of all-cause mortality, LVAD implant, or heart transplant soon after device implantation. Serum biomarkers and electrocardiographic and clinical variables were collected at implant. Multivariable analysis using the Cox proportional hazards model with stepwise selection method was used to fit the final model. RESULTS: Among 305 patients, 53 experienced the composite endpoint. In multivariable analysis, 5 independent predictors ("HF-CRT") were identified: high-sensitivity C-reactive protein >9.42 ng/L (HR = 2.5 [1.4, 4.5]), New York Heart Association functional class III/IV (HR = 2.3 [1.2, 4.5]), creatinine >1.2 mg/dL (HR = 2.7 [1.4, 5.1]), red blood cell count <4.3 × 10(6)/μL (HR = 2.4 [1.3, 4.7]), and cardiac troponin T >28 ng/L (HR = 2.7 [1.4, 5.2]). One point was attributed to each predictor and 3 score categories were identified. Patients with scores 0-1, 2-3, and 4-5 had a 3-year cumulative event-free survival of 96.8%, 79.7%, and 35.2%, respectively (log-rank, P < .001). CONCLUSION: A simple score combining clinical and readily available biomarker data can risk-stratify CRT patients for HF progression and death. These findings may help identify patients who are in need of closer monitoring or early application of more aggressive circulatory support.
BACKGROUND: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality among individuals with dyssynchronous systolic heart failure (HF). However, patient outcomes vary, with some at higher risk than others for HF progression and death. OBJECTIVE: To develop a risk prediction score incorporating variables associated with mortality, left ventricular assist device (LVAD) implant, or heart transplant in recipients of a primary prevention cardiac resynchronization therapy-defibrillator (CRT-D). METHODS: We followed 305 CRT-D patients from the Prospective Observational Study of Implantable Cardioverter-Defibrillators for the composite outcome of all-cause mortality, LVAD implant, or heart transplant soon after device implantation. Serum biomarkers and electrocardiographic and clinical variables were collected at implant. Multivariable analysis using the Cox proportional hazards model with stepwise selection method was used to fit the final model. RESULTS: Among 305 patients, 53 experienced the composite endpoint. In multivariable analysis, 5 independent predictors ("HF-CRT") were identified: high-sensitivity C-reactive protein >9.42 ng/L (HR = 2.5 [1.4, 4.5]), New York Heart Association functional class III/IV (HR = 2.3 [1.2, 4.5]), creatinine >1.2 mg/dL (HR = 2.7 [1.4, 5.1]), red blood cell count <4.3 × 10(6)/μL (HR = 2.4 [1.3, 4.7]), and cardiac troponin T >28 ng/L (HR = 2.7 [1.4, 5.2]). One point was attributed to each predictor and 3 score categories were identified. Patients with scores 0-1, 2-3, and 4-5 had a 3-year cumulative event-free survival of 96.8%, 79.7%, and 35.2%, respectively (log-rank, P < .001). CONCLUSION: A simple score combining clinical and readily available biomarker data can risk-stratify CRT patients for HF progression and death. These findings may help identify patients who are in need of closer monitoring or early application of more aggressive circulatory support.
Authors: John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi Journal: Eur Heart J Date: 2006-06-16 Impact factor: 29.983
Authors: Kenneth A Ellenbogen; Michael R Gold; Timothy E Meyer; Ignacio Fernndez Lozano; Suneet Mittal; Alan D Waggoner; Bernd Lemke; Jagmeet P Singh; Francis G Spinale; Jennifer E Van Eyk; Jeffrey Whitehill; Stanislav Weiner; Maninder Bedi; Joshua Rapkin; Kenneth M Stein Journal: Circulation Date: 2010-11-15 Impact factor: 29.690
Authors: Jagmeet P Singh; Helmut U Klein; David T Huang; Sven Reek; Malte Kuniss; Aurelio Quesada; Alon Barsheshet; David Cannom; Ilan Goldenberg; Scott McNitt; James P Daubert; Wojciech Zareba; Arthur J Moss Journal: Circulation Date: 2011-03-07 Impact factor: 29.690
Authors: Rutger J van Bommel; Carel Jan Willem Borleffs; Claudia Ypenburg; Nina Ajmone Marsan; Victoria Delgado; Matteo Bertini; Ernst E van der Wall; Martin J Schalij; Jeroen J Bax Journal: Eur Heart J Date: 2010-08-07 Impact factor: 29.983
Authors: Grace Lin; Bernard J Gersh; Eddie L Greene; Margaret M Redfield; David L Hayes; Peter A Brady Journal: Eur Heart J Date: 2010-11-10 Impact factor: 29.983
Authors: Matthias Dupont; John Rickard; Bryan Baranowski; Niraj Varma; Thomas Dresing; Alaa Gabi; Michael Finucan; Wilfried Mullens; Bruce L Wilkoff; W H Wilson Tang Journal: J Am Coll Cardiol Date: 2012-07-11 Impact factor: 24.094
Authors: Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Grigorios Giamouzis; Andrew L Smith; Syed A Agha; Sana Waheed; Sonjoy Laskar; John Puskas; Sandra Dunbar; David Vega; Wayne C Levy; Javed Butler Journal: J Am Coll Cardiol Date: 2009-01-27 Impact factor: 24.094
Authors: Emanuele Bertaglia; Giuseppe Arena; Domenico Pecora; Albino Reggiani; Antonio D'Onofrio; Pietro Palmisano; Antonio De Simone; Salvatore I Caico; Massimiliano Marini; Giampiero Maglia; Anna Ferraro; Francesco Solimene; Antonella Cecchetto; Maurizio Malacrida; Giovanni L Botto; Maurizio Lunati; Giuseppe Stabile Journal: Clin Cardiol Date: 2019-07-13 Impact factor: 2.882